BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:45 PM
 | 
Mar 11, 2010
 |  BC Extra  |  Company News

FDA panel discusses LABA safety trials

Members of FDA's Pulmonary-Allergy Drugs and Drug Safety and Risk Management advisory committees overwhelmingly voted that randomized controlled trials would best evaluate serious asthma outcomes with marketed long-acting beta-2 agonists (LABAs) when added to corticosteroids compared to corticosteroids alone to treat asthma. No official vote...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >